News

CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has dosed the first healthy volunteer in a clinical trial of its investigational drug VCA 894A, an antisense oligonucleotide (ASO) the company designed to treat CMT2S. This milestone marks early ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to share that Kailee Ward, Genetic Counseling Assistant at CMTA’s Center of Excellence at the University of Iowa Hospitals and Clinics and Research Support ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to announce the designation of Lisa Williams, MD, at UC Davis Health in Sacramento, California, as a CMTA Center of Excellence. Dr. Williams is a ...

CMT news out of Belgium: Augustine Therapeutics has officially dosed the first participant in a Phase I clinical trial of AGT-100216, the company’s experimental drug in development for Charcot-Marie-Tooth disease (CMT). According to the company, AGT-100216 is an HDAC6 inhibitor (HDAC6i). ...

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Applied Therapeutics on presenting new 24-month results from its Phase III CMT-SORD clinical trial at the 2025 Annual Meeting of the Peripheral Nerve Society (PNS). The findings ...